In The News

Cross-Border Ropes & Gray Team Represents Oxford Immunotec in its $74 million IPO

Practices: Life Sciences, Private Equity, Tax, Securities & Futures Enforcement, European Private Equity

A cross-border team of Ropes & Gray attorneys acted as company counsel in the $74 million IPO of ordinary shares of Oxford Immunotec Global PLC (Oxford), a public limited company incorporated in England and Wales, and its listing on the NASDAQ Global Market. J.P. Morgan and Piper Jaffray acted as joint book runners on the deal. 

Oxford is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. Its proprietary T-SPOT technology platform allows it to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. The company plans to use the net proceeds from the IPO to expand its sales, marketing and customer-service operations both in the United States and internationally, to boost its research and development work on immunology-related diagnostics, to repay debt, and for general corporate purposes. 

The Ropes & Gray deal team was led by life sciences partner Michael Beauvais (Boston) and included private equity transactions partner Will Rosen (London); Boston-based tax & benefits partners David Saltzman and Renata Ferrari; securities & public companies associate Tom Fraser (Boston); tax & benefits associates Ilce Kozaroski (London) and Alyssa Kollmeyer (Boston); London-based private equity transactions associate John Newton; corporate associates Will Michener (Boston) and Lisa Mikhail (Boston).
Cookie Settings